Taxol Adjuvant Benefit In Receptor-Positive Breast Cancer Not Yet Clear
Bristol-Myers Squibb's Taxol (paclitaxel) approval for sequential adjuvant therapy allows for use of the drug in estrogen and progesterone receptor-negative and positive tumors, although no benefit has been made clear in the receptor-positive group.
You may also be interested in...
The indication for Bristol-Myers Squibb's Taxol should refer physicians to the "clinical studies" section of labeling for information about receptor subgroup analyses, FDA's Oncologic Drugs Advisory Committee said Sept. 17 in recommending sequential administration of Taxol (paclitaxel) following chemotherapy for node-positive breast cancer.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials